A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of BIIB122 in Participants with Parkinson’s Disease
-
Enrollment
This study is currently enrolling. -
Associated Conditions
-
Research Area
Neuroscience Research -
Location
-
Principal Investigator
-
Sponsor
Biogen
You may be eligible to take part in the study because you have Parkinson’s Disease (PD). Only people who have been diagnosed with PD in the past 2 years and who are within the ages of 30 to 80 years can take part in the study. Also, a small number of participants may be taking a stable dose of medication (levodopa or monoamine oxidase-B inhibitors) for the management of PD symptoms.
Enrollment Form
This study is currently enrolling.